Organized immune cell interactions within tumors sustain a productive T-cell response.
Antigens, Neoplasm
/ immunology
CD4-Positive T-Lymphocytes
/ cytology
CD8-Positive T-Lymphocytes
/ cytology
Cell Differentiation
/ immunology
Dendritic Cells
/ immunology
Humans
Immunotherapy
Lymphocyte Activation
/ immunology
Lymphocytes, Tumor-Infiltrating
/ immunology
Neoplasms
/ immunology
T-Lymphocyte Subsets
/ cytology
CD4 T cells
CD8 T-cell differentiation
T-cell exhaustion
dendritic cells
lymphoid-like niches
Journal
International immunology
ISSN: 1460-2377
Titre abrégé: Int Immunol
Pays: England
ID NLM: 8916182
Informations de publication
Date de publication:
01 01 2021
01 01 2021
Historique:
received:
14
07
2020
accepted:
18
08
2020
pubmed:
23
8
2020
medline:
10
2
2022
entrez:
23
8
2020
Statut:
ppublish
Résumé
Tumor-infiltrating CD8 T cells are associated with improved patient survival and response to immunotherapy in various cancers. Persistent antigen leads to CD8 T-cell exhaustion, where proliferation/self-renewal and killing are divided within distinct subsets of CD8 T cells in the tumor. CD8 T-cell responses in chronic antigen settings must be maintained for long periods of time, suggesting that mechanisms that regulate chronic CD8 T-cell responses may differ from those in acute settings. Currently, factors that regulate the maintenance of stem-like CD8 T cells in the tumor or their differentiation into terminally differentiated cells are unknown. In this review, we discuss the role of dendritic cells in the activation and differentiation of CD8 T-cell subsets within secondary lymphoid tissue and tumors. In addition, we examine changes in CD4 T-cell differentiation in response to chronic antigens and consider how subset-specific mechanisms could assist the stem-like and terminally differentiated CD8 T-cell subsets. Finally, we highlight how tumor-infiltrating CD4 T cells and dendritic cells interact with CD8 T cells within organized lymphoid-like areas in the tumor and propose a CD8 T-cell differentiation model that requires the collaboration of CD4 T cells and dendritic cells. These organized interactions coordinate the anti-tumor response and control disease progression by mechanisms that regulate CD8 T-cell differentiation, which permit the maintenance of an effective balance of stem-like and terminally differentiated CD8 T cells.
Identifiants
pubmed: 32827212
pii: 5895925
doi: 10.1093/intimm/dxaa057
pmc: PMC7771196
doi:
Substances chimiques
Antigens, Neoplasm
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
27-37Subventions
Organisme : NCI NIH HHS
ID : R00 CA197804
Pays : United States
Informations de copyright
© The Japanese Society for Immunology. 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Cell. 2019 Feb 7;176(4):775-789.e18
pubmed: 30595452
Immunity. 2017 Feb 21;46(2):205-219
pubmed: 28190711
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Annu Rev Immunol. 2003;21:265-304
pubmed: 12524385
Cancer Cell. 2017 May 8;31(5):711-723.e4
pubmed: 28486109
Nature. 2018 May;557(7706):575-579
pubmed: 29769722
J Med Virol. 2004 Jan;72(1):52-9
pubmed: 14635011
Nat Rev Immunol. 2020 Jan;20(1):7-24
pubmed: 31467405
Nature. 2020 Feb;578(7793):122-128
pubmed: 32025013
Immunity. 2018 Oct 16;49(4):678-694.e5
pubmed: 30314757
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
J Clin Invest. 2004 Aug;114(4):468-71
pubmed: 15314682
Immunity. 2017 Nov 21;47(5):848-861.e5
pubmed: 29126798
Nat Rev Immunol. 2016 Mar;16(3):149-63
pubmed: 26875830
Science. 2015 May 15;348(6236):803-8
pubmed: 25837513
Annu Rev Med. 2018 Jan 29;69:301-318
pubmed: 29414259
Nat Commun. 2016 Dec 23;7:13720
pubmed: 28008905
Cell Rep. 2019 Dec 3;29(10):3019-3032.e6
pubmed: 31801070
Nucleic Acids Res. 2015 Jan;43(Database issue):D805-11
pubmed: 25355519
Curr Top Microbiol Immunol. 2011;350:39-65
pubmed: 20703965
Br J Cancer. 2011 Jun 28;105(1):93-103
pubmed: 21629244
Nature. 1998 Jun 4;393(6684):478-80
pubmed: 9624004
Immunity. 2013 Oct 17;39(4):687-96
pubmed: 24076049
Immunity. 2019 Sep 17;51(3):573-589.e8
pubmed: 31474513
Annu Rev Immunol. 2019 Apr 26;37:457-495
pubmed: 30676822
Nat Immunol. 2020 Apr;21(4):434-441
pubmed: 32205883
J Virol. 1994 Dec;68(12):8056-63
pubmed: 7966595
J Exp Med. 2011 Sep 26;208(10):1989-2003
pubmed: 21930769
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Nat Commun. 2020 Jan 31;11(1):661
pubmed: 32005826
Nat Immunol. 2019 Mar;20(3):326-336
pubmed: 30778252
Science. 2007 Jan 5;315(5808):107-11
pubmed: 17204652
Immunity. 2009 Jul 17;31(1):145-57
pubmed: 19604493
Annu Rev Immunol. 2019 Apr 26;37:173-200
pubmed: 30550719
Immunity. 2018 Apr 17;48(4):745-759.e6
pubmed: 29669252
Immunity. 2019 Dec 17;51(6):1043-1058.e4
pubmed: 31810882
Cancer Cell. 2005 Nov;8(5):369-80
pubmed: 16286245
Cell Res. 2017 Jan;27(1):109-118
pubmed: 27995907
J Virol. 2020 Sep 29;94(20):
pubmed: 32759317
J Immunol. 2017 Jul 15;199(2):792-805
pubmed: 28630092
Cancer Cell. 2016 Aug 8;30(2):324-336
pubmed: 27424807
Science. 2009 Jun 19;324(5934):1569-72
pubmed: 19423777
Int Rev Cell Mol Biol. 2019;342:149-173
pubmed: 30635090
J Exp Med. 1998 Dec 21;188(12):2205-13
pubmed: 9858507
Immunol Today. 1999 Aug;20(8):384-5
pubmed: 10431160
J Clin Oncol. 2016 Oct 10;34(29):3562-3569
pubmed: 27528724
Immunity. 2019 Jan 15;50(1):195-211.e10
pubmed: 30635237
Immunity. 2011 Dec 23;35(6):972-85
pubmed: 22177921
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Immunity. 2019 Dec 17;51(6):1028-1042.e4
pubmed: 31810883
Cancer Res. 2015 Apr 15;75(8):1635-44
pubmed: 25720800
Immunity. 2019 Jan 15;50(1):181-194.e6
pubmed: 30635236
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Nature. 2020 Apr;580(7801):E1
pubmed: 32238929
Immunity. 2016 Aug 16;45(2):415-27
pubmed: 27533016
Cell. 1989 Jul 28;58(2):293-303
pubmed: 2568889
Nat Immunol. 2016 Oct;17(10):1187-96
pubmed: 27487330
J Clin Oncol. 2018 Mar 10;36(8):773-779
pubmed: 29355075
Cancer Immunol Immunother. 2007 Nov;56(11):1743-53
pubmed: 17487490
Immunity. 2017 Apr 18;46(4):577-586
pubmed: 28410988
Immunity. 2020 Aug 18;53(2):335-352.e8
pubmed: 32610077
J Immunol. 2012 Feb 1;188(3):1156-67
pubmed: 22210916
Curr Opin Immunol. 2001 Apr;13(2):134-40
pubmed: 11228404
Nat Med. 2018 Oct;24(10):1628
pubmed: 30093729
Nature. 2017 Mar 30;543(7647):723-727
pubmed: 28329770
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
Cancer Cell. 2007 Feb;11(2):147-60
pubmed: 17292826
Cell. 2019 Apr 18;177(3):556-571.e16
pubmed: 30955881
Nature. 2016 Aug 2;537(7620):412-428
pubmed: 27501245
Cancer Cell. 2019 Jun 10;35(6):901-915.e4
pubmed: 31185213
Immunol Rev. 1996 Oct;153:85-106
pubmed: 9010720
Cell. 2015 Sep 10;162(6):1322-37
pubmed: 26296422
Nature. 2019 Dec;576(7787):465-470
pubmed: 31827286
Science. 2018 Nov 9;362(6415):694-699
pubmed: 30409884
Trends Mol Med. 2017 Dec;23(12):1072-1087
pubmed: 29137933
Nat Immunol. 2019 Aug;20(8):1059-1070
pubmed: 31308541
Nature. 2019 Oct;574(7780):696-701
pubmed: 31645760
Cell. 2019 Jan 10;176(1-2):404
pubmed: 30633907
JCI Insight. 2017 Jun 2;2(11):
pubmed: 28570278
J Clin Invest. 2006 Jul;116(7):1935-45
pubmed: 16778987
Immunity. 2020 May 19;52(5):825-841.e8
pubmed: 32396847
N Engl J Med. 2013 Jul 11;369(2):122-33
pubmed: 23724867
Immunol Rev. 2016 May;271(1):260-75
pubmed: 27088920
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
J Exp Med. 2011 May 9;208(5):987-99
pubmed: 21536743
Immunol Rev. 2008 Apr;222:129-44
pubmed: 18363998
Nat Rev Cancer. 2014 Feb;14(2):135-46
pubmed: 24457417
Nature. 2016 Sep 15;537(7620):417-421
pubmed: 27501248
Cold Spring Harb Perspect Biol. 2017 Jun 1;9(6):
pubmed: 28108486
Cancer Cell. 2014 Dec 8;26(6):938
pubmed: 28898680
J Clin Oncol. 2012 Jul 20;30(21):2678-83
pubmed: 22711850
J Immunol. 2000 Dec 1;165(11):6047-55
pubmed: 11086036
Nat Commun. 2017 Dec 6;8(1):1961
pubmed: 29213079
Annu Rev Immunol. 2004;22:329-60
pubmed: 15032581
Immunity. 2019 May 21;50(5):1132-1148
pubmed: 31117010
Proc Natl Acad Sci U S A. 2020 Feb 25;117(8):4292-4299
pubmed: 32034098
Cell. 2020 Jun 25;181(7):1612-1625.e13
pubmed: 32497499
J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):e38-40
pubmed: 21921725
Cell. 2017 Jun 15;169(7):1342-1356.e16
pubmed: 28622514
Blood. 2008 Jun 1;111(11):5326-33
pubmed: 18276844
Br J Cancer. 2006 Jan 30;94(2):275-80
pubmed: 16421594
Curr Opin Immunol. 2009 Apr;21(2):200-8
pubmed: 19285848
Immunity. 2019 Feb 19;50(2):302-316
pubmed: 30784578
Nat Med. 2001 Oct;7(10):1118-22
pubmed: 11590434
Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14987-92
pubmed: 18818309
Annu Rev Immunol. 2006;24:99-146
pubmed: 16551245
J Clin Invest. 2016 Sep 1;126(9):3447-52
pubmed: 27525433
Sci Immunol. 2016 Dec 23;1(6):
pubmed: 28018990
Clin Cancer Res. 2016 Aug 15;22(16):4057-66
pubmed: 26994146
Cell Rep. 2018 Jun 12;23(11):3262-3274
pubmed: 29898397
Nat Rev Immunol. 2018 Oct;18(10):635-647
pubmed: 30057419
Cancer Res. 1993 Sep 15;53(18):4391-8
pubmed: 8364935
J Immunol. 2005 Mar 1;174(5):2591-601
pubmed: 15728465
Cell. 2018 Jan 25;172(3):549-563.e16
pubmed: 29275860
Immunity. 2006 Jul;25(1):129-41
pubmed: 16860762